Rheumatic Vasculitis - Symptoms, Causes & Treatment

Rheumatic Vasculitis - Overview

Rheumatic vasculitis is an inflammatory disease of the blood vessels that develops as a complication of underlying rheumatic or autoimmune conditions. The immune system mistakenly attacks the vessel walls, leading to inflammation, narrowing or blockage of blood vessels. Small, medium and large vessels in various organ systems can be affected.

Causes and Pathogenesis

Rheumatic vasculitis most commonly occurs as a complication of existing autoimmune diseases. The most frequent underlying conditions include:

• Rheumatoid arthritis (chronic joint inflammation)
• Systemic lupus erythematosus
• Sjogren syndrome
• Scleroderma
• Polymyositis and dermatomyositis

In these conditions, an excessive immune response causes immune complexes or autoantibodies to damage vessel walls. Inflammatory mediators promote the infiltration of immune cells into the vessel wall, amplifying tissue injury.

Symptoms

The symptoms of rheumatic vasculitis are varied and depend on which vessels and organs are affected:

• Skin changes: purpura, ulcers, livedo reticularis, digital infarctions
• Peripheral neuropathy: numbness, tingling, weakness in the limbs
• Kidney involvement: blood or protein in the urine, impaired kidney function
• Eye involvement: scleritis, episcleritis
• Cardiovascular: angina, rarely myocardial infarction due to coronary involvement
• General symptoms: fever, weight loss, fatigue

Diagnosis

Diagnosing rheumatic vasculitis requires a thorough clinical assessment combined with targeted investigations:

• Laboratory tests: elevated inflammatory markers (CRP, ESR), autoantibodies (e.g. ANCA, ANA, RF), kidney function, complement levels
• Imaging: ultrasound, MRI or CT to visualise affected vessels
• Biopsy: tissue sample from affected areas (e.g. skin, kidney) for histological confirmation
• Angiography: when large vessel involvement is suspected

Treatment

Treatment of rheumatic vasculitis is guided by the severity of the condition and the organ systems involved. The primary goals are to suppress inflammation and prevent organ damage:

• Corticosteroids (e.g. prednisolone) as the first-line treatment for rapid inflammation control
• Immunosuppressants such as methotrexate, azathioprine or cyclophosphamide in severe disease
• Biologics such as rituximab in refractory cases
• Treatment of the underlying condition to reduce vasculitis activity

Beyond pharmacological therapy, regular monitoring is essential. Supporting joint health through nutrition may be a useful complementary approach. Our Joint Complex with UC-II for supplementary joint support provides further information on nutritional support for joint health.

Prognosis and Disease Course

The prognosis of rheumatic vasculitis depends strongly on the underlying condition, the extent of organ involvement and the response to therapy. With early diagnosis and consistent treatment, remission can be achieved in many cases. Severe courses involving kidney failure or cardiovascular complications are associated with increased morbidity.

People living with rheumatic diseases and ongoing joint inflammation may benefit from a holistic approach. Products such as our Joint Complex with UC-II as a supplementary preparation for joint health can be considered as part of a balanced diet and lifestyle.

Prevention

Specific prevention of rheumatic vasculitis is not possible due to its nature as an autoimmune complication. However, consistent treatment of the underlying rheumatic disease can help reduce the risk of developing vasculitis. General measures such as a balanced diet, regular physical activity and smoking cessation contribute to vascular health. For those interested in complementary support for joint health, our UC-II Joint Complex nutritional supplement for joint support offers additional information.

Frequently Asked Questions

What is the difference between rheumatic vasculitis and primary vasculitis?

Rheumatic vasculitis develops as a complication of an existing autoimmune disease such as rheumatoid arthritis. Primary vasculitis, by contrast, is an independent condition in which blood vessel inflammation is the primary disease itself, without an underlying autoimmune disorder being present.

Which organs are most commonly affected by rheumatic vasculitis?

The skin, peripheral nerves and kidneys are most frequently involved. Skin manifestations such as purpura or ulcerations are often the first visible signs. Kidney involvement can lead to impaired renal function and requires close monitoring. The eyes and cardiovascular system may also be affected as the disease progresses.

How is rheumatic vasculitis diagnosed?

Diagnosis involves a combination of clinical examination, laboratory tests (inflammatory markers, autoantibodies), imaging studies and in some cases a tissue biopsy. A biopsy from affected skin or kidney tissue is considered the gold standard for confirming the diagnosis.

Can rheumatic vasculitis be cured?

A complete cure is rare, but many patients achieve stable remission with consistent treatment. Therapy aims to control inflammation, prevent organ damage and maintain quality of life. Regular follow-up appointments are essential to monitor disease activity and adjust treatment as needed.

What role does nutrition play in rheumatic vasculitis?

A balanced, anti-inflammatory diet rich in vegetables, fruit, fish and healthy fats can support overall wellbeing in autoimmune conditions. However, diet does not replace medical therapy. Any nutritional supplements should always be discussed with the treating physician before use.

Which specialists treat rheumatic vasculitis?

A rheumatologist is primarily responsible for diagnosis and treatment. Depending on the organs involved, nephrologists (kidneys), dermatologists (skin), neurologists (nerves) or cardiologists (heart) may also be part of the care team. Interdisciplinary collaboration is essential in severe or complex cases.

References

1. Watts, R. A. & Scott, D. G. I. (2013). Epidemiology of the vasculitides. Current Opinion in Rheumatology, 15(1), 11-16.
2. Jennette, J. C. et al. (2013). 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, 65(1), 1-11.
3. Vassilopoulos, D. & Espinoza, L. R. (2003). Rheumatoid vasculitis. Current Rheumatology Reports, 5(2), 145-151.